Glycaemic control in acute coronary syndromes: prognostic value and therapeutic options

被引:44
作者
De Caterina, Raffaele [1 ,2 ]
Madonna, Rosalinda [1 ,2 ]
Sourij, Harald [3 ]
Wascher, Thomas [3 ,4 ]
机构
[1] Univ G DAnnunzio, Osped SS Annunziata, Inst Cardiol, I-66013 Chieti, Italy
[2] Univ G DAnnunzio, Osped SS Annunziata, Ctr Excellence Aging, I-66013 Chieti, Italy
[3] Graz Univ, Dept Internal Med, Metab & Vasc Biol Res Unit, Graz, Austria
[4] Hanuschkrankenhaus, Dept Internal Med 1, Vienna, Austria
关键词
Diabetes; Acute coronary syndromes; Glucose control; Insulin; Incretins; Glucagon-like peptide 1; ACUTE MYOCARDIAL-INFARCTION; GLUCAGON-LIKE PEPTIDE-1; INTENSIVE INSULIN THERAPY; ST-SEGMENT ELEVATION; LONG-TERM PROGNOSIS; DIABETIC-PATIENTS; CRITICALLY-ILL; GLUCOSE CONTROL; BLOOD-GLUCOSE; RISK-FACTOR;
D O I
10.1093/eurheartj/ehq162
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Type 2 diabetes and acute coronary syndromes (ACS) are widely interconnected. Individuals with type 2 diabetes are more likely than non-diabetic subjects to experience silent or manifest episodes of myocardial ischaemia as the first presentation of coronary artery disease. Insulin resistance, inflammation, microvascular disease, and a tendency to thrombosis are common in these patients. Intensive blood glucose control with intravenous insulin infusion has been demonstrated to significantly reduce morbidity and mortality in critically ill hyperglycaemic patients admitted to an intensive care unit (ICU). Direct glucose toxicity likely plays a crucial role in explaining the clinical benefits of intensive insulin therapy in such critical patients. However, the difficult implementation of nurse-driven protocols for insulin infusion able to lead to rapid and effective blood glucose control without significant episodes of hypoglycaemia has led to poor implementations of insulin infusion protocols in coronary care units, and cardiologists now to consider alternative drugs for this purpose. New intravenous or oral agents include the incretin glucagon-like peptide 1 (GLP1), its analogues, and dipeptidyl peptidase-4 inhibitors, which potentiate the activity of GLP1 and thus enhance glucose-dependent insulin secretion. Improved glycaemic control with protective effects on myocardial and vascular tissues, with lesser side effects and a better therapeutic compliance, may represent an important therapeutic potential for this class of drugs in acutely ill patients in general and patients with ACS in particular. Such drugs should be known by practicing cardiologists for their possible use in ICUs in the years to come.
引用
收藏
页码:1557 / U20
页数:10
相关论文
共 82 条
[1]   The difficult task of glycaemic control in diabetics with acute coronary syndromes: finding the way to normoglycaemia avoiding both hyper- and hypoglycaemia [J].
Abbate, A ;
Biondi-Zoccai, GGL .
EUROPEAN HEART JOURNAL, 2005, 26 (13) :1245-1248
[2]   The Extrapancreatic Effects of Glucagon-Like Peptide-1 and Related Peptides [J].
Abu-Hamdah, Rania ;
Rabiee, Atoosa ;
Meneilly, Graydon S. ;
Shannon, Richard P. ;
Andersen, Dana K. ;
Elahi, Dariush .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2009, 94 (06) :1843-1852
[3]   Cell signalling of glucagon-like peptide-1 action in rat skeletal muscle [J].
Acitores, A ;
González, N ;
Sancho, V ;
Valverde, I ;
Villanueva-Peñacarrillo, ML .
JOURNAL OF ENDOCRINOLOGY, 2004, 180 (03) :389-398
[4]   New treatments in type 2 diabetes: a focus on the incretin-based therapies [J].
Barnett, Anthony H. .
CLINICAL ENDOCRINOLOGY, 2009, 70 (03) :343-353
[5]   Newly detected abnormal glucose tolerance:: an important predictor of long-term outcome after myocardial infarction [J].
Bartnik, M ;
Malmberg, K ;
Norhammar, A ;
Tenerz, Å ;
Öhrvik, J ;
Rydén, L .
EUROPEAN HEART JOURNAL, 2004, 25 (22) :1990-1997
[6]   Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride [J].
Basu, Ananda ;
Charkoudian, Nisha ;
Schrage, William ;
Rizza, Robert A. ;
Basu, Rita ;
Joyner, Michael J. .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2007, 293 (05) :E1289-E1295
[7]   Cardiovascular disease [J].
Bloomgarden, ZT .
DIABETES CARE, 2006, 29 (05) :1160-1166
[8]   Impaired glucose metabolism predicts mortality after a myocardial infarction [J].
Bolk, J ;
van der Ploeg, T ;
Cornel, JH ;
Arnold, AER ;
Sepers, J ;
Umans, VAWM .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2001, 79 (2-3) :207-214
[9]  
Borch-Johnsen K, 1999, LANCET, V354, P617
[10]   Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury [J].
Bose, AK ;
Mocanu, MM ;
Carr, RD ;
Brand, CL ;
Yellon, DM .
DIABETES, 2005, 54 (01) :146-151